$SAGE
Sage Therapeutics, Inc.

2015 Q2 Form 10-Q Financial Statement

#000119312515288194 Filed on August 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.500M $1.800M
YoY Change 261.11% 125.0%
% of Gross Profit
Research & Development $18.60M $4.381M
YoY Change 324.63% 13.67%
% of Gross Profit
Depreciation & Amortization $100.0K $0.00
YoY Change
% of Gross Profit
Operating Expenses $25.06M $6.188M
YoY Change 304.96% 32.93%
Operating Profit -$25.06M -$6.188M
YoY Change 304.96% 32.93%
Interest Expense $41.00K $1.000K
YoY Change 4000.0%
% of Operating Profit
Other Income/Expense, Net -$9.000K -$5.000K
YoY Change 80.0%
Pretax Income -$25.00M -$6.200M
YoY Change 303.23% 31.91%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$25.03M -$6.192M
YoY Change 304.18% 33.02%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$896.1K -$258.3K
COMMON SHARES
Basic Shares Outstanding 27.86M shares 1.701M shares
Diluted Shares Outstanding 27.86M shares 1.701M shares

Balance Sheet

Concept 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $224.2M $49.10M
YoY Change 356.62%
Cash & Equivalents $224.2M $49.13M
Short-Term Investments
Other Short-Term Assets $3.300M $2.400M
YoY Change 37.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $227.5M $51.54M
YoY Change 341.39%
LONG-TERM ASSETS
Property, Plant & Equipment $285.0K $69.00K
YoY Change 313.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $700.0K $0.00
YoY Change
Total Long-Term Assets $965.0K $108.0K
YoY Change 793.52%
TOTAL ASSETS
Total Short-Term Assets $227.5M $51.54M
Total Long-Term Assets $965.0K $108.0K
Total Assets $228.5M $51.65M
YoY Change 342.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.195M $1.862M
YoY Change 179.0%
Accrued Expenses $5.164M $2.069M
YoY Change 149.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.00M $3.931M
YoY Change 179.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $22.00K $40.00K
YoY Change -45.0%
Total Long-Term Liabilities $22.00K $40.00K
YoY Change -45.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.00M $3.931M
Total Long-Term Liabilities $22.00K $40.00K
Total Liabilities $11.02M $3.971M
YoY Change 177.56%
SHAREHOLDERS EQUITY
Retained Earnings -$108.7M -$44.79M
YoY Change 142.77%
Common Stock $326.2M $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $217.5M -$44.79M
YoY Change
Total Liabilities & Shareholders Equity $228.5M $51.65M
YoY Change 342.34%

Cashflow Statement

Concept 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$25.03M -$6.192M
YoY Change 304.18% 33.02%
Depreciation, Depletion And Amortization $100.0K $0.00
YoY Change
Cash From Operating Activities -$18.40M -$5.300M
YoY Change 247.17% 23.26%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $129.1M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 129.6M -1.000M
YoY Change -13060.0%
NET CHANGE
Cash From Operating Activities -18.40M -5.300M
Cash From Investing Activities -100.0K 0.000
Cash From Financing Activities 129.6M -1.000M
Net Change In Cash 111.1M -6.300M
YoY Change -1863.49% 46.51%
FREE CASH FLOW
Cash From Operating Activities -$18.40M -$5.300M
Capital Expenditures -$100.0K $0.00
Free Cash Flow -$18.30M -$5.300M
YoY Change 245.28% 23.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28821252 shares
CY2015Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
52.50
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49127000
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28625403 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28625403 shares
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
326191000
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
31000
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1294000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
217451000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8554000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1269000
CY2015Q2 sage Accrued Development Expenses Current
AccruedDevelopmentExpensesCurrent
3036000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8066000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
227508000
CY2015Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3274000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
224234000
CY2015Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
641000
CY2015Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22000
CY2015Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
803000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5195000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5164000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108743000
CY2015Q2 us-gaap Liabilities
Liabilities
11022000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
228473000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
641000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11000000
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q2 us-gaap Assets
Assets
228473000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
285000
CY2015Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
39000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25621791 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25621791 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
188727000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1279000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
121885000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
574000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2429000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4687000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66845000
CY2014Q4 us-gaap Liabilities
Liabilities
7780000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129665000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
3000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0088 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18403308 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.28
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
641000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7757000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q4 us-gaap Assets
Assets
129665000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
39000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
128822000
CY2014Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
10000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1056000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127766000
CY2014Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
641000
CY2014Q4 sage Accrued Development Expenses Current
AccruedDevelopmentExpensesCurrent
2788000
CY2015Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2628571 shares
CY2015Q2 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
600000
CY2015Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129100000
CY2014Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.3175 pure
CY2014Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
18007575 shares
CY2014Q3 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
2300000
CY2014Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
94000000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10889000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y7D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0190 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1676864 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
us-gaap Net Income Loss
NetIncomeLoss
-11982000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13885000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
435000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11978000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
907000
us-gaap Share Based Compensation
ShareBasedCompensation
495000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1903000
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
41061000
us-gaap Operating Expenses
OperatingExpenses
11978000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-5000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
51955000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3424000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
495000
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001597553
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-385000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22000
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
sage Share Based Compensation Arrangement By Share Based Payment Award Estimated Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate
0.10 pure
sage Licensing Or Consultant Fees Paid In Common Stock
LicensingOrConsultantFeesPaidInCommonStock
127000
sage Public Offering Costs Included In Current Liabilities
PublicOfferingCostsIncludedInCurrentLiabilities
733000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-33049000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M13D
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0149 pure
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P10Y
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.57
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1749374 shares
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41898000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9244 pure
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
In connection with preparing for the IPO, the Company's board of directors and stockholders approved a 1-for-3.15 reverse stock split of the Company's common stock
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
Sage Therapeutics, Inc.
us-gaap Net Income Loss
NetIncomeLoss
-41898000
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-25027000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25027000
dei Trading Symbol
TradingSymbol
SAGE
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26765705 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
181000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
62000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2219000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41956000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
458000
us-gaap Share Based Compensation
ShareBasedCompensation
6747000
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
96468000
us-gaap Operating Expenses
OperatingExpenses
41956000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-181000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
129698000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31503000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129720000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
296000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6747000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10453000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2760000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
436000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
54000
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
sage Share Based Compensation Arrangement By Share Based Payment Award Estimated Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate
0.10 pure
sage Licensing Or Consultant Fees Paid In Common Stock
LicensingOrConsultantFeesPaidInCommonStock
1211000
sage Stockholders Equity Reverse Stock Split Effective Date
StockholdersEquityReverseStockSplitEffectiveDate
2014-07-02
sage Public Offering Costs Included In Current Liabilities
PublicOfferingCostsIncludedInCurrentLiabilities
137000
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y22D
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0182 pure
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.57
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19838303 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0215 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1700517 shares
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-6192000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7769000
CY2014Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6188000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2014Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1577000
CY2014Q2 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
6188000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4381000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
335000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1807000
CY2014Q2 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M16D
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0169 pure
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.90
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1749374 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8858 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27860332 shares
CY2015Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
41000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-25059000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000
CY2015Q2 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
25059000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18603000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5398000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6456000
CY2015Q2 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0

Files In Submission

Name View Source Status
0001193125-15-288194-index-headers.html Edgar Link pending
0001193125-15-288194-index.html Edgar Link pending
0001193125-15-288194.txt Edgar Link pending
0001193125-15-288194-xbrl.zip Edgar Link pending
d940847d10q.htm Edgar Link pending
d940847dex101.htm Edgar Link pending
d940847dex311.htm Edgar Link pending
d940847dex312.htm Edgar Link pending
d940847dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g940847new17.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sage-20150630.xml Edgar Link completed
sage-20150630.xsd Edgar Link pending
sage-20150630_cal.xml Edgar Link unprocessable
sage-20150630_def.xml Edgar Link unprocessable
sage-20150630_lab.xml Edgar Link unprocessable
sage-20150630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending